Zhixiang Jintai announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The clinical trial application for the GR2302 injection product under development was approved, and it was agreed to carry out clinical trials for chronic hepatitis B. GR2302 injection is a bispecific antibody developed independently by the company based on TCR simulated antibodies and anti-CD3 antibodies. It can recruit T cells to kill HBV-infected hepatocytes and is used to treat hepatitis B and liver cancer caused by HBV. As of the announcement date, no drugs with the same target have been approved for clinical trials in China.

Zhixiang Jintai announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The clinical trial application for the GR2302 injection product under development was approved, and it was agreed to carry out clinical trials for chronic hepatitis B. GR2302 injection is a bispecific antibody developed independently by the company based on TCR simulated antibodies and anti-CD3 antibodies. It can recruit T cells to kill HBV-infected hepatocytes and is used to treat hepatitis B and liver cancer caused by HBV. As of the announcement date, no drugs with the same target have been approved for clinical trials in China.